The Department of Health has asked us to conduct a Single Technology Appraisal of durvalumab for treating metastatic urothelial bladder cancer after chemotherapy. However, the company have advised that they will not be pursuing a licensing application for durvalumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
29 March 2017 Suspended, The Department of Health has asked us to conduct a Single Technology Appraisal of durvalumab for treating metastatic urothelial bladder cancer after chemotherapy. However, the company have advised that they will not be pursuing a licensing application for durvalumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance